Investigational drug · Phase 3
Dexpramipexole Dihydrochloride
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Obstructive Pulmonary Disease, Eosinophilic Asthma, Asthma; Eosinophilic.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 5, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
15
Any phase or sponsor naming "Dexpramipexole Dihydrochloride"
First trial start
2023
Jan 30, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Dexpramipexole Dihydrochloride", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Obstructive Pulmonary Disease
- Eosinophilic Asthma
- Asthma; Eosinophilic
- Asthma Attack
Approved drugs for the same conditions: Asthma · COPD · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "Dexpramipexole Dihydrochloride" as an intervention, largest first.
- A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.Pivotal-lookingTerminated
Areteia TherapeuticsIndustry
NCT05763121 · 1,061 participants · Start Jan 30, 2023 · Primary completion Dec 8, 2025
Drug: Dexpramipexole Dihydrochloride; Placebo · For: Eosinophilic Asthma; Asthma; Eosinophilic; Asthma
Sites: Bakersfield, California; La Palma, California; Newport Beach, California · 401 sites in all
- A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)Pivotal-lookingTerminated
Areteia TherapeuticsIndustry
NCT05813288 · 654 participants · Start Mar 27, 2023 · Primary completion Dec 8, 2025
Drug: Dexpramipexole Dihydrochloride; Placebo · For: Eosinophilic Asthma; Asthma; Eosinophilic; Asthma
Sites: Mobile, Alabama; Chandler, Arizona; Peoria, Arizona · 282 sites in all
- A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic AsthmaPivotal-lookingActive, not recruiting
Areteia TherapeuticsIndustry
NCT05748600 · 600 participants (planned) · Start Jan 30, 2023 · Primary completion Sep 2025
Drug: Dexpramipexole Dihydrochloride; Placebo · For: Eosinophilic Asthma; Asthma; Eosinophilic; Asthma Attack
Sites: Chandler, Arizona; Peoria, Arizona; Surprise, Arizona · 335 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT00721279 · 549 participants · Start Sep 2007 · Primary completion Oct 2008
Drug: Sifrol® (pramipexole dihydrochloride) · For: Restless Legs Syndrome
Sites: Absam, Austria; Absdorf, Austria; Afritz, Austria · 127 sites in all
- Phase III Long-Term Extension Study With DexpramipexolePivotal-lookingTerminated
Areteia TherapeuticsIndustry
NCT06388889 · 509 participants · Start Jun 12, 2024 · Primary completion Dec 8, 2025
Drug: Dexpramipexole Dihydrochloride · For: Eosinophilic Asthma
Sites: Bakersfield, California; Northridge, California; Coral Gables, Florida · 103 sites in all
Dr. D McIntosh & Dr. K Kjernisted Clinical Research Inc.Academic, hospital or other
NCT00893841 · 96 participants · Start Feb 2009 · Primary completion Jan 2013
Drug: quetiapine (Seroquel) XR; quetiapine (Seroquel) XR and 2 more · For: Bipolar Depression
Sites: San Diego, California; Kirkland, Washington; Edmonton, Canada · 9 sites in all
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07519278 · 49 participants · Start Mar 16, 2017 · Primary completion Apr 11, 2017
Drug: Test formulation(pramipexole dihydrochloride extended-release tablets); Reference formulation(MIRAPEX ER®) · For: Healthy
Sites: Chengdu, China
- A Study to Assess the Effects of Dexpramipexole in Participants With Eosinophilic COPDActive, not recruiting
Areteia TherapeuticsIndustry
NCT06533553 · 30 participants (planned) · Start Jul 9, 2024 · Primary completion Oct 2025
Drug: Dexpramipexole Dihydrochloride · For: Chronic Obstructive Pulmonary Disease
Sites: Conway, Arkansas; Newport Beach, California; Northridge, California · 23 sites in all
First Affiliated Hospital of Zhejiang UniversityAcademic, hospital or other
NCT04275492 · 30 participants · Start Jul 24, 2020 · Primary completion Oct 1, 2020
Drug: Praxol hydrochloride sustained release tablet Specification: 0.375mg/ tablet (in pramipexole hydrochloride); Pramipexole hydrochloride sustained-release tablet (Siforl®) Specification: 0.26mg/ tablet (in pramipexole) · For: Parkinson's Disease
Sites: Hanzhou, China
Bennett, James P., Jr., M.D., Ph.D.Individual
NCT00140218 · 30 participants · Start Aug 2005 · Primary completion Jan 2007
Drug: R(+) pramipexole dihydrochloride monohydrate · For: Amyotrophic Lateral Sclerosis
Sites: Pittsburgh, Pennsylvania; Charlottesville, Virginia
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Chronic Obstructive Pulmonary Disease
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- ItepekimabREGN3500, SAR440340Phase 39 trials
Sanofi · Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps, Bronchiectasis
- LunsekimigSAR443765Phase 39 trials
Sanofi · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps
- CM310Phase 35 trials
Keymed Biosciences Co.Ltd · Atopic Dermatitis, Moderate to Severe Asthma, Chronic Obstructive Pulmonary Disease
- TQC2731Phase 35 trials
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
- VerducatibBI 1291583Phase 34 trials
Boehringer Ingelheim · Bronchiectasis, Chronic Obstructive Pulmonary Disease
- AstegolimabPhase 33 trials
Roche (Genentech) · Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease (COPD)
- CM326Phase 33 trials
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. · Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps, Moderate to Severe Asthma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.